Mitochondria-targeting Pt/Mn porphyrins as efficient photosensitizers for magnetic resonance imaging and photodynamic therapy
Mitochondria-targeting Pt/Mn porphyrins as efficient photosensitizers for magnetic resonance imaging and photodynamic therapy
复制标题
线粒体靶向 Pt/Mn 卟啉作为磁共振成像和光动力治疗的有效光敏剂
DOI：
10.1016/j.dyepig.2019.03.048
复制
发表时间：
2019
影响因子：
4.5
通讯作者：
Wu Fengshou
中科院分区：
文献类型：
--
作者：
Yang Mengqian;Deng Jingran;Guo Ding;Sun Qi;Wang Zejiang;Wang Kai;Wu Fengshou
光动力疗法(PDT)作为一种微创、高效的抗癌治疗方法，受到了广泛的关注。然而，寻找更有效、毒性更低、生物相容性好、特异性高的光动力学光敏剂仍是人们非常期待的。在这里，我们合成并表征了一种新型的基于卟啉的光敏剂，它集成了磁共振成像(MRI)和荧光诊断以及线粒体靶向的光动力疗法。随着光敏剂剂量的增加，细胞存活率降低。在光照10 μm in的条件下，测得其IC50为30.74 g/mL。而对照组未经激光照射的HeLa细胞，即使在50 μg/mLPt-MnPor-PPh3浓度下，细胞存活率仍在80%以上。通过激光共聚焦扫描显微镜进一步研究了结合物的细胞摄取和亚细胞定位。结果表明，该偶联物在肿瘤细胞中具有良好的线粒体靶向性。此外，顺磁性金属锰离子的存在赋予了它们良好的磁共振性能，这为开发MRI引导和器官靶向PDT用于癌症治疗的新药提供了一种可行的合成策略。
Photodynamic therapy (PDT), as a minimally invasive and highly efficient anticancer approach, has received extensive attention. However, the search for more effective and less toxic photodynamic photosensitizers with good biocompatibility and high specificity are still highly expected. Herein, we synthesized and characterized a new porphyrin-based photosensitizer Pt-MnPor-PPh3, which integrated the magnetic resonance imaging (MRI) and fluorescence diagnostics and mitochondrial-targeted photodynamic therapy. The cell viabilities reduced with the increase of photosensitizer dose. The IC50of Pt-MnPor-PPh3was calculated to be 30.74 μg/mL under light irradiation for 10 min. In contrast, the cell viabilities of the control group, HeLa cells treated without laser irradiation, were still over 80% even at 50 μg/mL of Pt-MnPor-PPh3. The cellular uptake and subcellular localization of the conjugate were further evaluated through a confocal laser scanning microscope. The results showed that the conjugate had good mitochondrial-targeted properties in the cancer cells. Moreover, the presence of paramagnetic metal Mn ions in Pt-MnPor-PPh3endowed them with good MRI performances, which provided a feasible synthetic strategy to develop new medicines for MRI-guided and organelle-targeted PDT applications in cancer theranostics.